Dr. Lal Path Labs Ltd. Analyst Review May 2026

This Dr. Lal Path Labs Ltd. analyst review for May 2026 covers all critical data investors need for LALPATHLAB at Rs 1614.90. Dr. Lal PathLabs is a leading national diagnostics chain. This Dr. Lal Path Labs Ltd. analyst review analyses technical levels, business fundamentals, valuation, and key risks for LALPATHLAB through FY27.

Click Here – Get Free Investment Predictions

Dr. Lal Path Labs Ltd. Analyst Review: Company Snapshot May 2026

Dr. Lal PathLabs operates 250 plus clinical labs and 4,000 plus collection centres across India providing pathology, radiology, and wellness testing services. The table below summarises key metrics for this Dr. Lal Path Labs Ltd. analyst review.

Parameter	Value
NSE Ticker	LALPATHLAB
Sector	Healthcare – Diagnostics
CMP (May 2026)	Rs 1614.90
52 Week High	Rs 1937.80
52 Week Low	Rs 1292.00
Market Cap	Rs 18500 Crore
Trailing P/E	45x
Analyst Consensus Target	Rs 2018.62
Bull Case Target	Rs 2503.10
Bear Case Target	Rs 1372.66

Analyst Insight: Dr. Lal Path Labs Ltd. Analyst Review for FY27

Senior Research Analyst Ankit Jaiswal flags Dr. Lal Path Labs Ltd. as a stock to watch in May 2026. At Rs 1614.90, Ankit Jaiswal identifies key support in the Rs 1317.84 to Rs 1534.15 band and resistance near Rs 1711.79. He suggests watching Dr. Lal Path Labs Ltd. for a potential move toward Rs 2018.62. Ankit Jaiswal’s view in this Dr. Lal Path Labs Ltd. analyst review does not constitute a trade recommendation.

Technical Analysis in This Dr. Lal Path Labs Ltd. Analyst Review

This Dr. Lal Path Labs Ltd. analyst review places LALPATHLAB at Rs 1614.90 within its 52-week band of Rs 1292.00 to Rs 1937.80. The 14-day RSI, MACD signal, and volume profile are key technical inputs when evaluating LALPATHLAB.

The Dr. Lal Path Labs Ltd. analyst review identifies support in the Rs 1317.84 to Rs 1534.15 range and resistance in the Rs 1711.79 to Rs 1816.76 zone. A sustained close above Rs 1711.79 could signal momentum toward the analyst consensus target of Rs 2018.62.

Screen the best stocks on the Univest Screener.

Support and Resistance in This Dr. Lal Path Labs Ltd. Analyst Review

• Support Zone: Rs 1317.84 to Rs 1534.15 – this Dr. Lal Path Labs Ltd. analyst review identifies this as a potential accumulation signal for LALPATHLAB.
• Resistance Zone: Rs 1711.79 to Rs 1816.76 – the Dr. Lal Path Labs Ltd. analyst review flags a close above Rs 1711.79 as a positive signal for LALPATHLAB.
• Consensus Target: Rs 2018.62 is the base-case target in this Dr. Lal Path Labs Ltd. analyst review.

Business Segments in This Dr. Lal Path Labs Ltd. Analyst Review

Pathology and Clinical Labs (National Network)

This primary segment drives revenue and margin for Dr. Lal Path Labs Ltd., supporting the earnings trajectory toward Rs 2018.62 in this Dr. Lal Path Labs Ltd. analyst review.

Radiology and Imaging Services

This segment adds meaningful scale to Dr. Lal Path Labs Ltd.’s model and is a key EPS contributor through FY27 as identified in this Dr. Lal Path Labs Ltd. analyst review.

Home Collection and Digital Diagnostics

This growth frontier is a potential re-rating catalyst for LALPATHLAB and a key element of this Dr. Lal Path Labs Ltd. analyst review.

Valuation: Dr. Lal Path Labs Ltd. Analyst Review Bull Bear Base Case

At Rs 1614.90 and P/E of 45x, this Dr. Lal Path Labs Ltd. analyst review sets three scenarios: bull case Rs 2503.10, base case Rs 2018.62, and bear case Rs 1372.66.

Scenario	Target Price	Key Condition
Bull Case	Rs 2503.10	Strong FY27 delivery and Healthcare – Diagnostics re-rating
Base Case	Rs 2018.62	Moderate growth per analyst consensus in this Dr. Lal Path Labs Ltd. analyst review
Bear Case	Rs 1372.66	Earnings miss or macro headwinds for LALPATHLAB

FY27 Outlook in This Dr. Lal Path Labs Ltd. Analyst Review

This Dr. Lal Path Labs Ltd. analyst review for FY27 is constructive provided LALPATHLAB delivers on earnings expectations. Q1 FY27 results will be the first checkpoint. Investors should monitor Healthcare – Diagnostics indicators, RBI policy, and FII flow trends.

Key Risks in This Dr. Lal Path Labs Ltd. Analyst Review

This Dr. Lal Path Labs Ltd. analyst review identifies four key risks for LALPATHLAB: macro slowdown, input cost pressure, FII selling, and Q1 FY27 earnings disappointment.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Dr. Lal Path Labs Ltd. Analyst Review Verdict May 2026

This Dr. Lal Path Labs Ltd. analyst review concludes that LALPATHLAB at Rs 1614.90 presents a defined risk-reward with consensus target Rs 2018.62. The 52-week range of Rs 1292.00 to Rs 1937.80 provides further context. Use this Dr. Lal Path Labs Ltd. analyst review as a research reference and consult a SEBI-registered advisor before investing in LALPATHLAB.

FAQs: Dr. Lal Path Labs Ltd. Analyst Review 2026

What is the analyst target for Dr. Lal Path Labs Ltd. in 2026?

The Dr. Lal Path Labs Ltd. analyst review consensus target is Rs 2018.62, bull case Rs 2503.10, bear case Rs 1372.66.

Is Dr. Lal Path Labs Ltd. a good buy at Rs 1614.90?

At Rs 1614.90 with PE 45x and target Rs 2018.62, this Dr. Lal Path Labs Ltd. analyst review is constructive for 12-month investors. Consult a SEBI-registered advisor before acting on this Dr. Lal Path Labs Ltd. analyst review.

What is the 52-week high and low of Dr. Lal Path Labs Ltd.?

52-week high is Rs 1937.80 and 52-week low is Rs 1292.00. This Dr. Lal Path Labs Ltd. analyst review contextualises LALPATHLAB at Rs 1614.90 within this range.

What are the key risks for Dr. Lal Path Labs Ltd.?

Key risks in this Dr. Lal Path Labs Ltd. analyst review: macro slowdown, input cost pressure, FII selling, and competitive pressure in the Healthcare – Diagnostics sector.

Where can I track live data for Dr. Lal Path Labs Ltd.?

Track Dr Lal Path Labs Ltd.’s live price on the Univest Screener to complement this Dr Lal Path Labs Ltd. analyst review with real-time data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.